Viral vector-mediated gene transfer of neurotrophic factors is an emerging and promising strategy to promote the regeneration of injured peripheral nerves. Unfortunately, the chronic exposure to neurotrophic factors results in local trapping of regenerating axons or other unwanted side effects. Therefore, tight control of therapeutic gene expression is required. The tetracycline/ doxycycline-inducible system is considered to be one of the most promising systems for regulating heterologous gene expression. However, an immune response directed against the transactivator protein rtTA hampers further translational studies. Immunogenic proteins fused with the Gly-Ala repeat of the Epstein-Barr virus Nuclear Antigen-1 protein have been shown to successfully evade the immune system. In this article, we used this strategy to demonstrate that a chimeric transactivator, created by fusing the Gly-Ala repeat with rtTA and embedded in a lentiviral vector (i) retained its transactivator function in vitro, in muscle explants, and in vivo following injection into the rat peripheral nerve, (ii) exhibited a reduced leaky expression, and (iii) had an immune-evasive advantage over rtTA as shown in a novel bioassay for human antigen presentation. The current findings are an important step toward creating a clinically applicable potentially immune-evasive tetracycline-regulatable viral vector system.
INTRODUCTION
Traumatic injuries to the human peripheral nervous system often lead to severe motor and sensory deficits with a limited perspective of spontaneous axonal regeneration and functional recovery. Over the past decades, viral vector-mediated gene transfer of neurotrophic factors, axon guidance cues and transcription factors capable of promoting and guiding axonal regrowth as well as increasing survival of remaining neurons have emerged as a promising treatment strategy.
1,2 Glial cell line-derived neurotrophic factor (GDNF) has, through its effects on outgrowth and survival of motoneurons, emerged as an important candidate to enhance peripheral nerve regeneration. 3, 4 Lentiviral (LV) vector-mediated overexpression of GDNF during peripheral nerve regeneration has shown promising results but its uncontrolled expression leads to trapping of regenerating axons also known as the 'candy store' effect. [5] [6] [7] The development of a viral vector capable of regulating GDNF expression is therefore essential and could possibly further enhance axonal regeneration and functional outcome.
To achieve this, a regulatable vector should possess several essential characteristics. First, it should allow a rapid and efficient on-and-off switch of GDNF expression. Second, the activation of GDNF expression should solely depend on the presence of an inducer drug, which is safe and well tolerated in humans. Finally, a regulatable vector system should exhibit a low potential of eliciting an immune response in the peripheral nervous system. Over the past years, four main systems for in vivo transgene regulation have emerged from animal studies: the tetracycline 8, 9 and rapamycin-inducible systems, 10 the mammalian steroid receptor (tamoxifen and mifepristone) 11, 12 and the insect steroid receptor (ecdysteroid) system. 13 Of these, the tetracycline inducible system has been the most commonly studied and is at this moment considered the most potent and clinically relevant. 14 As its original development, 8 where transgene expression was repressed in the presence of the inducer drug tetracycline (so called tet-off), several major improvement in the tetracycline inducible system have readied this system for clinical translation. These include (i) the development of a more relevant tet-on system, 9 in which transgene expression is dependent on the binding of a tetracycline/doxycycline (Dox)-activated transactivator rtTA to a tet-operator controlled promoter; (ii) the development of a transactivator with increased sensitivity to the inducer drug Dox, and (iii) reduced activity in the absence of Dox causing so called 'leaky expression'. 15 Importantly, the inducing drug Dox is a well-tolerated antibiotic drug that has been administered orally and intravenously in humans for over 30 years and achieves excellent tissue penetration. Multiple in vivo studies have shown promising results regulating a large selection of transgenes including GDNF in a variety of tissues using the tet-on system. 14, [16] [17] [18] Unfortunately, preclinical studies in non-human primates revealed that long-term regulation of transgene expression was hampered by an active loss of genetically modified cells. [19] [20] [21] This loss resulted from a rapid cellular and humoral response targeted against the cells that expressed the transactivator rtTA. These findings currently exclude in vivo applicability of the tetracycline inducible system for the human peripheral nervous system. During evolution, many viruses have developed effective immune-evasive mechanisms. 22, 23 The Epstein-Barr virus (EBV), also called human herpes virus 4 requires the Epstein-Barr Nuclear-Antigen-1 protein (EBNA-1) to maintain stability of its genome during latency. To evade cytotoxic T-cell-mediated destruction, EBNA-1 possesses a long Gly-Ala repeat (GAr) that has been shown to prevent antigenic peptide presentation to major histocompatibility complex class I molecules. Previously, in a proof-of-concept study, we showed that fusing the GAr to the N-terminus of rtTA could possibly create a functional and immunologically inert transactivator (GArrtTA). 24 In this study, we embedded our GArrtTA-based system in a LV vector and investigated the effects of GAr fusion on GArrtTAmRNA and protein biosynthesis. We evaluated the capacity of GArrtTA to regulate transgene expression in vitro, ex vivo using muscle explants and in vivo following application in the rat peripheral nerve. We show that the GArrtTA-based system retains its transactivator function in vitro and in vivo in the peripheral nerve, displays reduced leaky expression, and has an immuneevasive advantage over rtTA in a novel bioassay for human antigen presentation.
RESULTS
The effects of GAr on rtTA biosynthesis In order to examine the possible effects resulting from the fusion of the Gly-Ala repeat to rtTA on protein biosynthesis, we performed an in vitro side by side comparison of rtTA and GArrtTA expression. We first created three independent LV vector batches of rtTA and GArrtTA and titered each by measuring genomic integration in HEK293T cells (Figure 1) . We then performed a titer-matched serial dilution in HEK293T in which we measured viral genomic integration, (GAr) rtTA mRNA and protein synthesis. As expected following titer-matched infection, we observed similar integration of all six viruses (P = not significant; Figure 2a ). Subsequently, we measured (GAr) rtTA mRNA expression and observed a sevenfold lower expression in GArrtTA compared with rtTA-expressing cells (P o0.01; Figure 2b ). Interestingly, western blot analysis of (GAr) rtTA protein expression showed an inverted fivefold increase in GArrtTA compared with rtTA-expressing cells (P o0.01; Figures 2c and d) . In summary, fusion of the Gly-Ala repeat to rtTA led to a reduction in mRNA expression while paradoxically increasing protein levels.
The effects of GAr on rtTA function We next evaluated the effects of the fusion of GAr to rtTA on its transactivating capacity. To assess (GAr) rtTA function, we created a HEK293T cell line expressing firefly luciferase under the control of a tet-operator-controlled promoter (TRE-Luc). In this cell line, at equal genomic integration and in the presence of the maximum non-toxic dose of Dox (10 μM), 25 both rtTA and GArrtTA successfully induced luciferase expression. There was, however, an approximately 20-fold lower induction by GArrtTA (data not shown). In light of these results, we decided to investigate the possibility to increase the multiplicity of infection (MOI) of GArrtTA to correct for this loss of function and compare the overall Dox responsiveness (Figure 3a) . In our TRE-Luc cell line, we performed a titer-matched infection (for GArrtTA and rtTA) and the experimentally determined (20-fold increased) function-matched infection for GArrtTA. Cells were stimulated with increasing amounts of Dox (0, 0.01, 0.1, 1 and 10 μM) for 24 h. In line with our previous observations, low Dox concentrations were sufficient to induce near maximum transactivation by rtTA but not by GArrtTA. 24 By increasing both Dox levels and GArrtTA levels (function-matched group), we were, however, able to induce similar levels of transgene expression for GArrtTA and rtTA ( Figure 3a) . Interestingly, in the absence of Dox, we observed a reduced leaky expression in not only the GArrtTA titer-matched group but also the GArrtTA function-matched group compared with rtTA. To further investigate this leaky expression, we decided to perform a study in our TRE-Luc cell line infected with increasing amounts of the rtTA or GArrtTA virus (MOI of 0.01, 0.1, 1, 10 and 50) in the absence of Dox (Figure 3b ). Although increasing rtTA concentrations showed a linear increase in leaky expression, we were unable to detect any leaky expression in the GArrtTA group (P o 0.001). These findings indicate that fusion of the Gly-Ala repeat to rtTA modifies its capacity to transactivate the tet-operator-controlled promoter, thus effectively reducing its transactivator efficiency and leaky expression.
Regulation of gene expression ex vivo
As an intermediate step toward in vivo GDNF regulation, we evaluated the capacity of our transactivator to regulate luciferase expression in ex vivo rodent tissue explants. For this, we injected muscle explants of the rat gastrocnemius muscle with a two-vector approach. Titer-matched GArrtTA or rtTA vectors were injected together with a TRE-Luc vector. An additional function-matched group of GArrtTA was added (20-fold increase). Over a total period of 7 weeks we successfully performed three full on/off cycles mediated through the addition or removal of Dox, showing first that fusion of GAr to rtTA still allows the release of GArrtTA from the tet-operator-controlled promoter and second that a two-vector approach is feasible for in vivo translation (Figures 3c and d) . Furthermore, as observed in vitro, increasing GArrtTA successfully resulted in a system with comparable efficiency (GArrtTA function match versus rtTA; P = not significant). These findings suggest that at adequate levels GArrtTA can tightly regulate gene expression and that a two-vector approach is realistic for in vivo translation.
Regulation of gene expression in vivo Our next aim was to regulate the expression of a therapeutically relevant protein mediated through GArrtTA in vivo. More specifically, we wanted to assess whether GArrtTA could (i) induce GDNF expression in the rat peripheral nerve, (ii) lead to biologically relevant levels of GDNF expression and (iii) permit long-term regulation in an immune-competent environment. Figure 1 . Schematic representation of the constructs and their titers. The classical transactivator rtTA and the potentially non-immunogenic transactivator GArrtTA under the control of the constitutively active cytomegalovirus (CMV) promoter were embedded in second-generation lentiviral vectors (CMV-rtTA and CMV-GArrtTA, respectively). In addition, lentiviral vectors encoding for firefly luciferase and GDNF under the control of the tetracycline response element were created (TRE-Luc and TRE-GDNF, respectively). In the presence of Dox, the transactivator protein (rtTA or GArrtTA) can bind to the TRE and transcription of the gene of interest (firefly luciferase or GDNF) is initiated. Three independent batches of CMV-rtTA and CMV-GArrtTA and a single batch of TRELuc, TRE-GDNF and CMV-GFP were produced. Transducing units per ml (TU ml − 1 ) for the LV-GFP were manually quantified by counting transduction events in HEK293T cells. The genomic integration of viral WPRE of all stocks was measured in HEK293T cells and the ratio between TU ml − 1 and genomic WPRE content of LV-GFP was used to calculate relative TU ml − 1 titers of all stocks.
To evaluate this, we performed a side by side comparison of the rtTA-and GArrtTA-based systems in vivo. Using our two-vector approach, we injected in a 1:1 ratio either CMV-rtTA or CMV-GArrtTA and TRE-GDNF in the left sciatic nerve of Wistar rats (n = 48). During a total period of 18 weeks, GDNF expression in the sciatic nerve was measured by ELISA at five different time points (weeks 2, 4, 6, 8 and 18; Figure 4 ). Supplementing the regular diet with Dox for a period of two weeks (weeks 0-2) successfully induced GDNF expression in the peripheral nerve in all groups (week 2). This showed that GArrtTA is a fully functional transactivator in vivo and demonstrated the excellent penetration of Dox in the rat peripheral nerve. A return to the regular diet (weeks 2-4) resulted in a return to baseline (week 4). An additional two rounds of Dox including a late time point (weeks 4-6 and 16-18) successfully resulted in a renewed increase of GDNF expression (weeks 8 and 18) albeit at lower levels compared with the first round (week 2). Overall, the induced expression levels of GDNF were comparable to previously observed levels achieved with a constitutively active CMV promoter driving expression. 26 This shows that GArrtTA has the capacity to switch on-and-off biologically relevant expression levels of GDNF. In line with the in vitro findings, we observed almost no leaky expression in the GArrtTA group in the absence of Dox (weeks 4 and 8). In contrast two out of eight animals in the rtTA group had considerable levels of GDNF in the absence of Dox (187 pg cm − 1 at week 4 and 227 pg cm − 1 at week 8). All together these findings demonstrate for the first time that GArrtTA is a fully functional transactivator with an almost undetectable leaky expression that can efficiently regulate gene expression in vivo. Unexpectedly, during our 18 weeks follow-up, we did not observe a selective loss of function in the rtTA group. This finding suggests that a vigorous immune response directed against rtTA does not occur in the peripheral nerve of Wistar rats. This therefore precluded the possibility to confirm the immune-evasive advantages of GArrtTA in our in vivo model.
GAr protects from human cytotoxic T-cell-mediated destruction
The immunogenicity of rtTA has, however, been extensively described in non-human primates and remains a putative risk for further human translational studies. [19] [20] [21] Therefore, our final goal was to validate the immune-evasive advantage of the fusion of GAr to rtTA in a human bioassay. In order to achieve this we set up an in vitro assay were we fused the HLA-A2 restricted CMV pp65-derived epitope NLVPMVATV to the C-terminal end of rtTA or GArrtTA (figure 5b). We subsequently monitored the death of rtTA [pp65]-modified HLA-A2 target cells induced by CMV-specific CD8 + T-cells (CTL). To assess CTL-induced apoptosis, we used a caspase-3-sensitive firefly luciferase. 27 In apoptotic conditions, this non-active cyclic luciferase is cleaved by caspase-3 at the tetrapeptide sequence: Asp-Glu-Val-Asp (DEVD) resulting in the return of luciferase into an active form. We created a LV vector in which the expression of the DEVD-cyclic-luciferase reporter cassette (cFLucDEVD) is driven by the constitutively active CMV promoter.
To determine whether such reporter could be used to monitor CMV CTL-induced apoptosis, HLA-A2 + HEK293T cells were incubated with synthetic NLVPMVATV peptides derived from the pp65 of CMV and exposed to increasing amounts of CMV NLVPMVATV/HLA-A2-specific CTLs. Overnight incubation resulted in an up to fourfold increase in light emission upon incubation with pp65-specific CTL only in the cells loaded with peptide (P o 0.0001; Figure 5a ). Of note, in the absence of peptide, no significant increase in luciferase activity was detectable upon CTL addition. Similarly, transfection of rtTA[pp65] in HEK293T cells induced an up to 10-fold increase in luciferase activity upon incubation with pp65-specific CTL, demonstrating efficient processing and presentation of the antigenic epitope to CTLs (Figure 5d ). In the same experimental setup, although transfection of GArrtTA[pp65] gave rise to similar protein expression, as shown by western blot analysis (Figure 5c ), pp65 presentation to CMV-CTLs was remarkably impaired by the fused Gly-Ala repeat. A 70% reduction of luciferase activity for the highest T-cell concentration was observed (rtTA v GArrtTA, P o 0.0001).
DISCUSSION
In this article, we present a tetracycline-inducible LV vector system based on a potentially non-immunogenic transactivator, which allows the controlled expression of a gene of interest in vivo. To achieve this, we embedded the classical regulatable system, based on the immunogenic rtTA transactivator, and our system, based on the potentially non-immunogenic GArrtTA transactivator in LV vectors and performed a side by side comparison in vitro in a cell line, ex vivo in muscle explants and in vivo in the rodent peripheral nerve. Finally, we developed a novel human in vitro assay to validate the capacity of GArrtTA to evade human cytotoxic T-cell-mediated destruction validating the potential clinical relevance of our system. We show here that GArrtTA is a fully functional transactivator, which possesses significantly enhanced immune-evasive properties that can successfully regulate transgene expression in vivo.
The EBNA-1 permits latency of the EBV in humans. It has an essential role in the episomal maintenance of the EBV genome while successfully evading immune surveillance. 28 Unraveling its composition has revealed that its immune-evasive characteristics are the result of a long irregular copolymer repeat of glycine and alanine (GAr) present at its N-terminal. This repeat successfully prevents EBNA-1 presentation by major histocompatibility complex classI molecules disabling cytotoxic T-cell recognition and destruction. 29, 30 Fusion of GAr at the N-terminus of different immunogenic proteins successfully resulted in their immune evasion. 6, 31, 32 Previously, in an in vitro proof-of-concept study, we showed that fusion of GAr to rtTA could possibly create a functional and immunologically inert transactivator. 24 In this article, we embedded the classical rtTA and our transactivator GArrtTA in a LV backbone. To investigate the effects of GAr on rtTA biosynthesis, the mRNA and protein expression levels were quantified following equal genomic integration of both vectors. Interestingly, fusion of GAr created an increase in protein expression (7:1 ratio GArrtTA v rtTA), whereas mRNA availability was paradoxically reduced (1:5 ratio GArrtTA v rtTA). The increased GArrtTA protein availability is in line with the capacity of GAr to increase protein stability and inhibit proteasomal degradation. 29, 33 Initial reports conferred the immune-evasive advantages of GAr to this inhibition hypothesizing that proteasome-mediated degradation was necessary for antigen presentation by the major histocompatibility complex class I. Recently, however, it has become clear that the majority of presented antigenic peptides are not derived from proteasomal degradation but rather from early translation initiation events from reading frames throughout the mRNA. 34 Indeed, not proteasomal inhibition but inhibition of in-cis translation initiation permits the immune evasion of GAr. 35, 36 In line with this theory, reducing the overall presence of 'immunogenic' viral mRNA could be an additional strategy used by EBNA-1 to evade immune presentation. In EBV, EBNA-1 has been shown to regulate different viral promoters including its own. 37, 38 A plausible strategy to create a stable and nonimmunogenic setting during EBV latency could be a negative feedback of EBNA-1 causing the reduction of viral mRNA while maintaining functional levels of this essential and immune-evasive protein. This homeostasis seems ideal for a regulatable vector as constant high transactivator levels are desirable while immune presentation must be minimized.
Fusion of GAr to rtTA results in a three times larger protein (248 versus 678 amino acids). Therefore, we investigated the effects of this fusion on the transactivating capacity of rtTA. Fusion of the GAr to rtTA leads to a reduction in transactivation efficiency. Fortunately, increasing transactivator concentrations resulted in a near normal efficiency of the induction of transgene expression. Importantly, under these conditions, leaky expression (binding of Figure 5 . GAr protects in-cis fused transgenes from human cytotoxic T-cell-mediated recognition and destruction. (a) Validation of our bioassay. H293T cells possessing a caspase-3-sensitive firefly luciferase were exposed to the CMV pp65-derived peptide NLVPMVATV (Pep). Following the exposure to increasing amounts of the HLA-A2-specific CMV-CTLs, apoptosis and luciferase activity were induced (P o0.001). the transactivator in the absence of Dox) was not increased. These characteristics highlight that GArrtTA is an effective transactivator with the advantage of showing almost no leaky expression. Over the years, the modification of rtTA has created highly efficient and sensitive transactivators in vitro. 15, 39, 40 The question remains, however, if contaminants in food and other comestible products could, in such sensitive transactivators, undesirably induce chronic transgene expression in a clinical setting. On the other hand, an insensitive transactivator might be impossible to activate or cause unwanted side effects from the required high Dox levels such as nephrotoxicity or photosensitivity.
14 It is important to note that the concentrations of Dox used here are approximately 100-fold higher than the recommended dose for clinical use. 41 To investigate whether it was possible to regulate transgene expression through the less sensitive GArrtTA and successfully evade immune-mediated destruction of rtTA, we performed a comparative study of the two systems in vivo using LV-mediated delivery of the two transactivators to the rat peripheral nerve.
We demonstrated GDNF expression in the rat peripheral nerve following LV transduction through the addition or removal of Dox for a total period of up to 18 weeks. The oral administration of Dox was sufficient to allow rtTA and GArrtTA to equally induce previously reported biologically relevant levels of GDNF expression in the peripheral nerve. 26 In line with our in vitro findings, we found a reduced leaky expression in GArrtTA. This is clinically relevant because unwanted side effects following the prolonged application of several neurotrophic factors have been documented. 2 Unexpectedly, during our 18 weeks follow-up, we did not observe a loss of function in the rtTA group. Earlier reports from our group have shown that in the rodent peripheral nerve cells expressing foreign proteins following LV transduction are rapidly cleared by the immune system. 42 Our results apparently suggest that a vigorous response against rtTA is absent in the peripheral nerve of Wistar rats. The immunogenicity of rtTA has, however, been extensively shown in non-human primates and precludes the use of this system in translational studies in human subjects. [19] [20] [21] Using a caspase-sensitive firefly luciferase 27 in combination with human cytotoxic T cells, we demonstrated that GArrtTA displays a significant immune-evasive advantage in human cells. Interestingly, even though this immune-evasion was highly efficient, it was not complete. Combining this assay with our TRE-Luc cell line would be an ideal screen to discover novel enhanced GArrtTA transactivators in the future. Reducing the size of GAr or modifying the existing GArrtTA through viral evolution, an elegant method described by Das and colleagues, 39, 40 could potentially create a more efficient transactivator that can be activated at a clinically acceptable dose of Dox, 41 while conserving its non-leaky and immune-evasive properties.
In conclusion, we have developed a fully functional LV vector system capable of regulating transgene expression in vivo via a tetracycline inducible transactivator that possesses enhanced immune-evasive properties. The findings reported in this article present an important step toward the milestone of creating a clinically applicable tetracycline-regulatable viral vector system.
MATERIALS AND METHODS

DNA constructs
Second generation LV transfer plasmids flanked by the constitutively active CMV promoter and the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) were created by replacing the GFP sequence from pRRL-CMV-GFP-WPRE by the coding sequence for rtTA and GArrtTA. 24 Transfer plasmids where expression of GDNF and luc2 (pGL4.10, Promega, Leiden, The Netherlands) was driven by the inducible tet responsive element (TRE) for GDNF and luc2 were created by replacing the CMV promoter by seven repeats of the tet operator DNA sequence fused with a minimal CMV promoter (Figure 1) . 43 pRRL-CMV-cFluc-DEVD-WPRE was generated by removing the cFluc-DEVD fragment from pcDNA3.1-cFluc-DEVD 27 with PmeI/PmeI and ligating it into pRRL-CMV-WPRE opened by SmaI. The pp65 epitope-containing constructs were generated by mutagenic PCR using the following primers: 5′-GACATGCTCCCCGGGAACTTGGTACC AATGGTTGCTACTGTTTAACTAAGTAAGGATCCG-3′; 5′-CGGATCCTTACTTAG TTAAACAGTAGCAACCATGGTACCAAGTTCCCGGGGAGCATGT-3 on pRRL-CMV-rtTA-WPRE and pRRL-CMV-GArrtTA-WPRE (Figure 5b ). The pp65 (NLVPMVATV)-encoding sequence is underlined. The constructs were validated by restriction analysis using the KpnI site in the mutant constructs shown in bold in the primers sequences.
LV production and tittering LV stocks were generated as previously described 32, 44, 45 in three independent rounds of production. Briefly, for each batch of LV, two 15-cm Petri dishes containing 12.5 × 10 6 HEK293T in Iscove's modified Dulbecco's medium (IMDM) containing 10% fetal calf serum (FCS), 1% penicillin/streptomycin (P/S) and glutamax (Invitrogen, Carlsbad, CA, USA) were prepared. All cells were maintained at 37°C in a humidified atmosphere of 5% CO2 . Using branched polyethylenimine (Sigma, St Louis, MO, USA), a triple transfection with the LV transfer, packaging (pCMVdeltaR8.74) and envelope (pMD.G.2) plasmid was performed (ratio 3:2:1, total DNA 90 μg per plate). After 14 h, the medium was replaced by IMDM containing 2% FCS, 1% P/S and glutamax. After 24 h, the medium was harvested, filtered through a 0.22-μM filter and concentrated by ultracentrifugation at 20 000 r.p.m. for 2.5 h in a SW32Ti rotor (Beckman Coulter BV, Woerden, The Netherlands). Viral pellets were resuspended in PBS pH 7.4, aliquoted and stored at − 80°C until further use.
Serial dilutions (10 -2 , 10 -3
, 10 -4 and 10 -2 to -7 for LV-GFP) of all viral stocks were used to infect 2 × 10 5 HEK293T in IMDM containing 2% FCS, 1% P/S and glutamax seeded in poly-L-lysine-coated 24-well culture plates. After 48 h, (1) the number of transducing units per ml (TU ml ). Briefly, cells were harvested and gDNA was extracted (DNeasy Blood & Tissue Kit, Qiagen, Venlo, The Netherlands). Viral-mediated transgene integration was measured using primers directed against the LV WPRE on an ABI 7900HT detection system (Applied Biosystems, Gouda, The Netherlands) using the SYBR green PCR kit (Applied Biosystems). WPRE primers were as follows: 5′-TTCCC GTATGGCTTTCATTT-3′ and 5′-GAGACAGCAACCAGGATTTA-3′. All expression values were normalized to that of the reference gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). GAPDH primers were as follows: 5′-TGCACCACCAACTGCTTAGC-3′ and 5′-CGCATGGACTGTGGTCATGA-3′. The ratio between the TU ml − 1 and gDNA WPRE content of the LV-GFP stock was used to calculate relative TU ml − 1 titers for all stocks on the basis of their gDNA WPRE content.
In-vitro biosynthesis comparison
Titer-matched serial dilutions of the three independently produced viral batches of rtTA and GArrtTA were performed in three (one for genomic DNA (gDNA), one for mRNA and one for protein extraction) 24-well culture plates pre-coated with poly-L-lysine and seeded with 2 × 10 5 HEK293T in IMDM containing 2% FCS, 1% P/S and glutamax. All cells were harvested 48 h post transduction. To quantify genomic integration, gDNA from three dilutions (MOI: 0.5, 5, 50) was extracted and analyzed for viral WPRE integrating events as described above. To determine rtTA mRNA expression, RNA from three dilutions (MOI: 0.2, 1, 5) was extracted using 250 μl TRIzol reagent (Invitrogen) per well. RNA was treated with DNase I (Invitrogen) and 1 μg was reverse transcribed using a QuantiTect Reverse Transcription Kit (Qiagen) according to manufacturer's protocol. Quantitative PCR was performed as described above with primers specific for rtTA: 5′-CACCTACCACCGATTCTATG-3′ and 5′-ACAGCTCAATTGCTTGTTTC-3′ and GAPDH. All expression values were normalized to that of GAPDH.
Western blot
Cells were treated with RIPA lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, SDS 0.1%, 0.5% sodium deoxycholate, 1% NP40 and protease inhibitors). Proteins were seperated by electrophoresis on an acrylamide/ bisacrylamide SDS-polyacrylamide gel electrophoresis gel transferred to Immobilon-P (Immobilon-P transfer membrane (polyvinylidene difluoride); Millipore, Etten-Leur, The Netherlands) and immunoblotted for rtTA, which was detected with anti-TetO2 antibody (1:1000; MoBiTec, Göttingen, Germany) and the loading control used was anti-actin (1:5000, clone C4; 
Creation of a TRE-Luc cell line
In a 96-well culture plate a single well was seeded with 1 × 10 3 HEK293T in IMDM containing 2% FCS, 1% P/S and glutamax. Twenty-four hours post seeding, the cells were transduced with a TRE-Luc LV vector at an MOI of 100. Twenty-four hours later, the medium was refreshed and we transduced the cells an additional time at an equal MOI of 100. The next day we collected five single cells and grew them to confluency in unique wells in a 96-well culture plate in IMDM containing 10% FCS, 1% P/S and glutamax. Once confluent, each unique well was reseeded in a new well in two separate 24-well culture plates. gDNA was extracted from each well from one plate and TRE-Luc integration was measured as described above using primers directed against the Luc2 gene. Luc2 primers were as follows: 5′-CACATATCGAGGTGGACATT-3′ and 5′-GCATGAAGAACTGCAAGCTA-3′. Normalization of TRE-LUC to that of the reference gene GAPDH revealed that all five clones express between 0.5 and 1.6 copies of TRE-LUC per cell. This is under the assumption that HEK293T cell are diploid and harbor two copies of the GAPDH gene per cell. As HEK293 cells are known to be hypotriploid (see for more information http://www.atcc.org), the actual TRE-LUC copy number is probably slightly higher. Clone #2 (1.4 copies per cell) was used for all experiments.
Luciferase activity
To measure luciferase activity, D-luciferin sodium salt (Regis Technologies, Morton Grove, IL, USA) diluted in PBS was added to each well to obtain a final concentration of 375 μg ml 
Dox responsiveness and leakiness assay
A total of four 24-well culture plates pre-coated with poly-L-lysine were seeded with 2 × 10 5 TRE-Luc HEK293T in IMDM containing 2% FCS, 1% P/S and glutamax. For the Dox responsiveness, three plates were used. Each single plate was transduced with three independently produced viral batches of rtTA (MOI: 0.5), GArrtTA (titer matched, MOI: 0.5) or GArrtTA (function matched, MOI: 10). Twenty-four hours post transduction, the medium was refreshed and supplemented with different concentrations of Dox (0, 10 -3, -2, -1, 0, 1 μM). Forty-eight hours post transduction, luciferase activity was measured. For the leakiness assay, a titer-matched serial dilution of the three independently produced viral batches of rtTA and GArrtTA (MOI: 10 -3, -2, -1, 0, 1 and 50) was performed in the remaining plate. Twenty-four hours post transduction, the medium was refreshed but no Dox was added. Forty-eight hours post transduction, luciferase activity was measured.
Experimental animals
A total of 48 female Wistar rats (200-250 g; Harlan, Horst, The Netherlands) were used. Animals were housed under standard conditions at a 12:12 h light/dark cycle with regular (weeks 3, 4, 7 to 16 weeks) or Dox (6 g kg − 1 ) enriched food (TD.09282, Harlan; weeks 1, 2, 5, 6 and 16-18) and water ad libitum. Experimental procedures were performed in accordance with the European Guidelines for the Care and Use of Laboratory Animals (86\609\EEC) and the local committee for laboratory animal welfare and experimentation.
Ex vivo assay A total of 16 muscle explants of rat gastrocnemius muscle were harvested from female Wistar rats (approximately 0.8 cm 3 ), divided into groups (n = 4) and kept in culture in two 12-well plates in IMDM containing 2% FCS, 1% P/S and glutamax for a total period of 44 days. Using a two-vector approach, a titer-matched CMV-rtTA (2.3E+09 TU ml − 1 ) and CMV-GArrtTA (1.0E+10 TU ml − 1 ) and a function-matched CMV-GArrtTA (20-fold increase) diluted in PBS, pH 7.4, to create a total volume of 9 μl were mixed with 1 μl of a TRE-Luc vector (2.0E+10 TU ml − 1 ). An additional PBS-injected control group was added. The explants were injected using an operating microscope with 10 μl of each viral vector solution. The injection was performed with a glass needle fixed to a 10-μl Hamilton syringe. Fast green (Sigma, Zwijndrecht, The Netherlands) was added to the viral vector solution to aid in the visualization of the injection procedure. Every 3-4 days medium was refreshed and luciferase expression was measured as described above except that the ROI was reduced to the muscle explant and the best exposure time was determined automatically. The medium was supplemented with 2 μM of Dox a total of three times (days 7-10, 24-28 and 41-44) and two extra medium washes of the explants were performed upon return to regular medium.
Surgical procedures
All animals were anesthetized using isoflurane (Isoflo, Abbott, Hoofddorp, The Netherlands). Following the splitting of the left gluteal muscle, the sciatic nerve was exposed. Starting 5 mm distal to the internal obturator tendon, the sciatic nerve was injected using a glass needle as described above through an operating microscope with 2 μl of a viral vector solution. The viral spread was subsequently marked proximally with a 10/0 epineural suture (Ethilon, Johnson & Johnson, Amersfoort, The Netherlands). The left sciatic was injected with a mix of either 1 μl CMV-rtTA (2.3E+09 TU ml − 1 ) or CMV-GArrtTA (1.0E+10 TU ml − 1 ) and 1 μl TRE-GDNF (2.3E+10 TU ml − 1 ). The wound was closed and a single dose of buprenorphine of 0.03 ml per 100 g body weight (Temgesic, Schering-Plough B.V., Maarssen, The Netherlands) was injected for postoperative analgesia. Animals were kept at 37°C until fully recovered.
GDNF ELISA
At 2, 4, 6, 8 (n = 8) and 18 (n = 16) weeks post-injection, animals were euthanized using pentobarbital (sodium pentobarbital; 0.11 ml per 100 g, Sanofi Sante, Maassluis, The Netherlands). The sciatic nerve was re-exposed by splitting the gluteal muscle and the epineurial marking suture was localized. A 1.5-cm segment distal to this suture was dissected. This segment was snap frozen on dry ice. To quantify the amount of GDNF, the nerve segments were homogenized in a mortar cooled with dry ice and containing liquid nitrogen and resuspended in 250 μl lysis buffer (137 mM NaCl, 20 mM Tris-HCl, pH 8.0, 1% Nonidet P40, 10% glycerol, 0.1% polysorbate 20, 0.5 mM sodium othonovadate and 1 tablet per 50 ml of Roche total protease inhibitor (Roche, Almere, The Netherlands)). The concentration of GDNF was measured with an ELISA kit (Emax #g7620, Promega, Madison, WI, USA) on high binding ELISA plates (Nunc-Immuno Maxisorp #439454). The procedure was performed following the manufacturer's instructions and the final GDNF concentration was expressed in pg cm − 1 of nerve segment.
Human cytotoxic T lymphocytes
For maintenance and expansion, pp65CMV-directed CTLs were cultured for two weeks with irradiated allogeneic PBMCs, irradiated CMV pp65 peptide-pulsed HLA-A2-expressing EBV-LCL in IMDM supplemented with 10% human serum, 0.5% LeucoA, 0.1 ng ml − 1 of recombinant human (rh)-interleukin (IL)-12, 10 ng ml − 1 of rh-IL7, 25 U ml − 1 of rh-IL-2 and 5 ng ml − 1 of rh-IL-15. Cells were frozen in a solution of 20% human pooled serum and 10% dimethyl sulfoxide and kept in liquid nitrogen until use. Upon thawing, cells were allowed to rest in IMDM supplemented with 10% human serum, IL-2 (50 U ml − 1 ) and IL-15 (0.1 ng ml − 1 ).
In-vitro apoptosis assay
To measure apoptosis in target cells, we used a caspase-3-sensitive luciferase reporter as previously described. 27 cFluc-DEVD-transduced HEK293T cells were transfected in suspension using polyethylenimine with 1 μg rtTA [pp65] or 1 μg GArrtTA [pp65] and plated in a 96-well plate in IMDM containing 10% FCS, 1% P/S and glutamax. Twenty-four hours post transfection, the medium was removed and modified cells were incubated with increasing amounts of HLA-A2-specific CTLs directed against pp65 (ranging from~1:1 to 10:1 effector/target ratio). After 24 h co-culture, cells were lysed with a luciferase lysis buffer (25 mmol l − 1 of Tris-HCl pH = 7.8, 2 mmol l − 1 of trans-1,2-diaminocyclohexane-N,N,N′,N′-tetraacetic acid, 2 mmol l − 1 of dithiothreitol, 10% glycerol, 1% Triton X-100).
Luciferase activity, reflecting the caspase-3 activity, was measured by luminometry (Luciferase Assay System, Promega). Experiments were performed in triplicate for every effector/target ratio used. Luciferase activity in the absence of CTLs was set to 1 and results are shown as relative luciferase activity.
Statistical analysis
All data were presented as mean ± s.e.m. and subjected to nonparametric statistical analysis using two-way analysis of variance test with Bonferroni correction using GraphPad Prism software (GraphPad, San Diego, CA, USA). A value of Po 0.05 was considered statistically significant.
